OMXC252,184.31+0.74%
EUR/DKK7.4610+0.01%
Novo Nordisk BDKK 604.40+1.23%
Vestas WindDKK 115.30-0.52%
DAX18,947.50+0.31%
S&P 5005,473.20+0.48%
Brent Crude$82.15-0.37%
10Y DK Gov2.89%+0.04
Gold$2,341.80+0.19%
OMXC252,184.31+0.74%
EUR/DKK7.4610+0.01%
Novo Nordisk BDKK 604.40+1.23%
Vestas WindDKK 115.30-0.52%
DAX18,947.50+0.31%
S&P 5005,473.20+0.48%
Brent Crude$82.15-0.37%

Equity Analysis

Structured fundamental and quantitative research on Danish and Nordic-listed equities — from index constituents to emerging small-cap opportunities.

All analysis published here is for informational and educational purposes only. Axiom does not provide investment advice. Please consult a licensed financial adviser before acting on any information.

Our Equity Research Approach

Axiom's equity research covers the full capital structure of listed companies with a primary focus on Nasdaq Copenhagen. Our analysis integrates quantitative screening, fundamental review, and macro context to produce structured assessments of companies, sectors, and market dynamics.

We employ multiple valuation frameworks — including discounted cash flow modelling, comparable company analysis (EV/EBITDA, P/E, P/B multiples), dividend discount models, and sum-of-the-parts analysis for conglomerates. Each method is selected based on the nature of the business and sector norms.

Financial analyst drawing on whiteboard with equity valuation model showing discounted cash flow calculations, revenue projections and comparable company analysis metrics

Valuation Frameworks We Apply

Discounted Cash Flow (DCF)

Projects future free cash flows and discounts at WACC. Particularly suited to stable cash-generative businesses. Sensitive to terminal value assumptions and discount rate selection.

Relative Valuation

EV/EBITDA, P/E, EV/Sales and P/B ratios benchmarked against sector peers and historical ranges. Provides market-relative context for valuation positioning.

Dividend Discount Model

Used for mature, dividend-paying companies. Gordon Growth Model and multi-stage variants applied depending on dividend policy stability and payout ratio history.

Sum-of-the-Parts

Applied to conglomerates with distinct business segments. Each division is valued separately using the most appropriate methodology, then aggregated with net debt adjusted.

OMXC25 Fundamental Snapshot

CompanyMkt Cap (DKKbn)P/E (TTM)EV/EBITDADiv. YieldROE
Novo Nordisk B2,74838.4x27.1x0.9%67.2%
A.P. Møller-Mærsk B2048.1x4.2x3.8%12.4%
Vestas Wind Systems115N/M14.6x0.0%-3.1%
Genmab15224.7x17.3x0.0%28.4%
Ørsted148N/M11.8x2.4%-8.2%
Coloplast B19629.3x20.8x2.1%41.6%
DSV27918.2x12.4x0.6%18.7%
Carlsberg B8719.6x9.8x2.7%16.2%

Key Sector Themes — Denmark 2024

Healthcare / Pharma
GLP-1 Dominance & Pipeline Expansion
Novo Nordisk's semaglutide franchise continues to drive earnings upgrades, with Wegovy approvals expanding into cardiovascular indications. Pipeline depth across competitors remains thin near-term. Valuation stretched by historical standards but justified by earnings growth trajectory.
Renewable Energy
Offshore Wind Margin Pressure Persists
Vestas and Ørsted face continued pressure from supply chain normalisation lag, higher interest rates compressing project economics, and contract renegotiation complexity. Long-term structural demand intact but near-term earnings visibility challenged.
Shipping & Logistics
Freight Rate Normalisation Following 2021–2022 Boom
A.P. Møller-Mærsk earnings have normalised sharply from post-pandemic highs. Management is executing a structural diversification strategy, with logistics acquisitions reducing pure container shipping exposure. Valuation now more reasonably positioned.
Financials
Danish Banks Benefiting from Rate Environment
Danske Bank, Jyske Bank, and Sydbank are seeing NIM expansion as interest rates normalise. Asset quality remains robust reflecting low unemployment in Denmark. Dividend capacity and buyback programmes are supportive near-term catalysts.

Access Full Equity Research Reports

Our detailed reports include complete financial models, scenario analysis, sector peer comparisons, and historical valuation context — available individually or via subscription.